Objectives: To evaluate the efficacy of the recently launched b-lactam/b-lactamase inhibitor combinations ceftazidime/avibactam and ceftolozane/tazobactam against ESBL-producing Escherichia coli and Pseudomonas aeruginosa strains.
Introduction
MDR including resistance to broad-spectrum cephalosporins and ultimately to carbapenems is nowadays commonly observed worldwide in Enterobacteriaceae and in Pseudomonas aeruginosa. 1 Resistance to broad-spectrum cephalosporins may occur by different mechanisms, including permeability defects and efflux overproduction. However, production of broadspectrum b-lactamases is the most significant mechanism leading to such resistance. 2 Hence, resistance to cephalosporins may occur through overproduction of AmpC b-lactamases, for which corresponding genes may be intrinsic in some species (such as P. aeruginosa, Enterobacter cloacae and Serratia marcescens) or acquired in Klebsiella pneumoniae or Escherichia coli, or by the acquisition of ESBLs.
Recently, two novel drug combinations have been launched, namely ceftazidime/avibactam and ceftolozane/tazobactam. GES-and PER-like enzymes, and BEL-, TEM-and CTX-M-like enzymes have been rarely identified. 9 Furthermore, the carbapenem-hydrolysing KPC enzymes possess an ESBL hydrolysis spectrum, but additionally hydrolyse carbapenems. They are increasingly identified in Enterobacteriaceae (mainly K. pneumoniae, but also E. coli), but remain rarely identified in P. aeruginosa. 10 One specific group of b-lactamases quite frequently identified in P. aeruginosa corresponds to GES enzymes, with GES-1 being an ESBL-sparing carbapenem, 11 whereas variants GES-2 and GES-5 possess significant carbapenemase activity.
12-14 GES-6, also possessing significant carbapenemase activity and originally identified in a K. pneumoniae isolate from Greece, 15 has recently been identified in P. aeruginosa. 16 We recently showed that GES-6 production is the source of acquired resistance to ceftolozane/tazobactam while not affecting the susceptibility to ceftazidime/avibactam. 17 The objective of our study was therefore to evaluate the relative impact of different ESBLs on susceptibility to ceftolozane/tazobactam and to ceftazidime/avibactam, either in E. coli or in P. aeruginosa backgrounds. Those two bacterial species were retained since E. coli represents a common community-acquired pathogen and P. aeruginosa a common hospital-acquired pathogen.
Materials and methods

Bacterial isolates
A series of ESBL-encoding genes was cloned and expressed in E. coli or P. aeruginosa recipient strains. Those ESBLs were derivatives of bla TEM , bla SHV , bla CTX-M , bla VEB , bla PER , bla GES and bla BEL . Donor strains are listed in Table 1 . In addition, the two carbapenemase genes bla KPC-2 and bla VIM-2 were added. P. aeruginosa PAO1 and E. coli TOP10 were used as recipient strains. 17 
Cloning experiments
Cloning of all ESBL-encoding genes was performed in the shuttle and broad-host range pUCp24 using PCR amplicons encompassing the entire coding sequence of all respective genes. 18 Primers used for PCR amplification of the ESBL genes are listed in Table S1 (available as Supplementary data at JAC Online). Electroporation of the recombinant plasmids and expression of the respective ESBL genes were performed in the E. coli TOP10 background. 17 Subsequently, electroporation of those same recombinant plasmids was performed in the P. aeruginosa PAO1 background. Selection was made on plates containing 100 mg/L ticarcillin and 30 mg/L gentamicin for both E. coli and P. aeruginosa transformants.
Susceptibility testing
MIC values were determined in triplicate by Etest (AB bioMérieux; Solna, Sweden) or broth microdilution (for ceftolozane alone) as previously described. 17 Interpretation was based on EUCAST breakpoints, ceftazidime/ avibactam resistance being defined as .8 mg/L for Enterobacteriaceae and P. aeruginosa, and ceftolozane/tazobactam resistance as .1 mg/L for Enterobacteriaceae and .4 mg/L for P. aeruginosa. 19 In order to further evaluate the respective contributions of the b-lactam agent (ceftazidime or ceftolozane) and that of the b-lactamase inhibitor (avibactam or tazobactam, respectively), MICs were determined not only at the usual ratio concentrations (inhibitor concentrations at 4 mg/L), but also at higher concentrations (8 and 16 mg/L, respectively).
b-Lactamase activities
Cultures of E. coli TOP10 harbouring recombinant plasmids and therefore producing the different ESBLs tested were grown overnight at 37 C in 1 L of brain heart infusion medium with amoxicillin (100 mg/L). The bacterial suspension was pelleted, resuspended in 10 mL of 100 mM phosphate buffer (pH 7), disrupted by sonification (20 min for 30 s of sonication and 50 s of rest at 20 kHz) with a Vibra Cell 75186 (Thermo Fisher) and centrifuged for 1 h at 11000 g and 4 C. b-Lactamase crude extracts were used for specific activity measurements performed at 30 C in 100 mM sodium phosphate (pH 7.0). The initial rates of hydrolysis were determined with a GENESYS 10S UV-Vis Spectrophotometer (Thermo Scientific). The following wavelengths/ absorption coefficients were used: benzylpenicillin, 232 nm/#1100 M #1 cm
#1
; ceftazidime, 260 nm/#8660 M #1 cm
; and ceftolozane, 254 nm/#6810 M #1 cm
. IC 50 s were determined for clavulanic acid, tazobactam and avibactam. Various concentrations of these inhibitors were pre-incubated with the crude extract of the enzyme for 5 min at 30 C to determine the concentrations that reduced the hydrolysis rate of 100 lM nitrocefin by 50%. Results are expressed in micromolar units. The total protein content was measured using a Bradford assay.
Results
Among the 11 ESBL-producing P. aeruginosa clinical isolates, 10 were resistant to ceftolozane/tazobactam whereas most remained susceptible to ceftazidime/avibactam ( Table 1 ). The ESBL-producing E. coli (CTX-M-15) was susceptible to both combinations. Notably, the KPC-2-producing P. aeruginosa isolate was susceptible to ceftazidime/avibactam, but resistant to ceftolozane/tazobactam.
Expression of the ESBL genes in E. coli TOP10 gave variable MIC values of ceftazidime/avibactam that remained in the susceptibility range (Table 2) . However, the MIC of ceftazidime/avibactam for the bla PER-1 -positive recombinant strain was 8 mg/L, which actually corresponds to the breakpoint value. This latter result was probably the consequence of a very high MIC of ceftazidime conferred by PER-1 activity, which was confirmed by the lowest MIC observed when combining ceftazidime with a higher concentration of avibactam ( Table 2) . MICs of ceftolozane/tazobactam for those recombinant E. coli strains were also variable, but, notably, several values remained in the resistance range, including those for the GES-1 and GES-6 producers, as well as for the PER-1, BEL-1 and BEL-2 producers (Table 2) . Notably, some high MIC values observed could be clearly explained by a combination of two features, namely a high hydrolysis rate toward ceftolozane and a lower inhibition by tazobactam, as for GES-6 and PER-1 (Table 3) . Increasing the concentration of tazobactam significantly decreased the MIC of ceftazidime for the GES-1 and GES-5 producers, but not for the GES-6 and PER-1 producers ( Table 2 ). The two carbapenemase-producing E. coli recombinant strains (KPC-2 and VIM-2) were resistant to ceftolozane/tazobactam, regardless of the tazobactam concentration used ( Table 2) .
Expression of the ESBL genes in P. aeruginosa PAO1 did not confer resistance to ceftazidime/avibactam except for the PER-1 producer (Table 4 ). This latter recombinant strain was the one with the highest MIC of ceftazidime, correlating with the poor activity of avibactam as an inhibitor toward PER-1 compared with other ESBLs (Table 3) , this feature being confirmed by the still high MICs of ceftazidime observed even with higher concentrations of avibactam ( Table 2) . MICs of ceftolozane/tazobactam for recombinant P. aeruginosa strains varied considerably, with an overall high resistance rate observed for the GES-6, CTX-M-2, PER-1, BEL-1, BEL-2 and SHV-2a producers (Table 4) . Of note was the discrepancy observed between the GES-1 and GES-2 producers on the one hand and the GES-5 and GES-6 producers on the other hand. This result is in accordance with recent results that we have obtained showing that a serine residue at position 170 in either b-lactamase GES-5 or GES-6 (while GES-1 and GES-2, respectively, possess glycine and asparagine residues at that position) is responsible for a decreased sensitivity to tazobactam. Increasing the tazobactam concentration did not significantly modify the MICs of ceftolozane, except for the GES-1 recombinant strain ( Table 2 ). As expected, the two carbapenemase-producing P. aeruginosa recombinant strains (KPC-2 and VIM-2) were also resistant to ceftolozane/ tazobactam.
Overall, two of the ESBL-producing P. aeruginosa recombinant strains were resistant to both ceftazidime/avibactam and ceftolozane/tazobactam combinations, namely those producing CTX-M-2 and PER-1.
Discussion
We showed here that ESBL acquisition may significantly counteract the activity of recently launched cephalosporin/b-lactamase inhibitor combinations. Our data showed that ceftazidime/avibactam seems to be a very effective option, not only against ESBLproducing E. coli as reported in other studies, but also against ESBL-producing P. aeruginosa. In a recent study performed by Livermore et al., 20 the prevalence of ESBL-producing (unknown determinant) Enterobacteriaceae susceptible to ceftazidime/avibactam was 99.7%, among which only 3.8% initially remained susceptible to ceftazidime, thus showing an extremely high efficacy of the inhibitor. Looking at the susceptibility to ceftolozane/tazobactam among ESBL-producing E. coli recovered from healthcare infections in Latin America, Pfaller et al. 21 found a rate of 9.2% of resistance, whereas it was very high (61.8%) in ESBLproducing K. pneumoniae. Here we showed that production of ESBLs in E. coli does not impact the susceptibility to ceftolozane/ tazobactam, which is mainly due to the excellent activity of ceftolozane as an antibiotic.
In that same study from Pfaller et al., 21 the rate of resistance to ceftolozane/tazobactam among ceftazidime-resistant P. aeruginosa was found to be 34.8%, for which the mechanism of resistance to ceftazidime was not determined (probably corresponding to a majority of AmpC overproducers). In a recent surveillance programme among isolates from US hospitals and assessing the susceptibility of Enterobacteriaceae to ceftolozane/tazobactam, a rate of 87.5% of susceptibility was found among noncarbapenemase-and ESBL-producing isolates. Here we showed that production of an ESBL in P. aeruginosa may significantly affect the efficacy of ceftolozane/tazobactam, although susceptibility to ceftazidime/avibactam was preserved.
Of note, the very interesting activity of avibactam as a b-lactamase inhibitor was evidenced here with ceftazidime as substrate, but may also be extremely valuable by enhancing the b-lactam activity of various b-lactams. By increasing the concentrations of the respective inhibitors in the ceftazidime/avibactam and ceftolozane/tazobactam combinations, we observed some significant drops in terms of MIC values for only some recombinant strains, namely both the GES-1-and GES-5-producing E. coli and P. aeruginosa strains, respectively, while they remained almost unchanged for all the others, including the GES-6 producers. This highlights further that high MICs of the two drug combinations conferred by GES-1 and GES-5 might be counteracted by increased concentrations of the inhibitor. However, pharmacokinetic/pharmacodynamic data measured for those drug combinations show that the respective b-lactam/b-lactamase inhibitor ratio remains stable in urine. 22, 23 Further work is now needed to evaluate the respective activities of ceftazidime/avibactam and ceftolozane/tazobactam toward a large collection of ESBL-producing E. coli and P. aeruginosa clinical isolates.
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